# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Stanton et al.	)	Group Art Unit:	1632	TER
Serial No.:	09/641,802	)	Examiner:	Unknown	
	No.: Unknown	ĺ			600/2900
Filed:	August 17, 2000	)			8
i nod.	71ugust 17, 2000	)			
For:	USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND				
	ANALOGS THEREOF TO PROMOTE NEURAL CELL DIFFERENTIATION				

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

In accordance with the continuing duty of candor and good faith that is to be demonstrated before the United States Patent and Trademark Office (USPTO), enclosed is a copy of one document cited in an International Search Report, Application No. PCT/US00/22777, which is not already of record in the present matter. Enclosed for the Examiner's information is a copy of the search report with the document. Also enclosed herewith is a copy of one document which Applicants bring to the Examiner's attention as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 form is respectfully requested. Pursuant to the provisions of MPEP §609, Applicants further request that a copy of the 1449 form, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Supplemental Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

## Supplemental Inf rmation Disclosure Statement

Applicant(s): Stanton et al. Serial No.: 09/641,802 Confirmation No.: Unknown Filed: August 17, 2000

For: USE OF COLOSTRININ, CONSTITUENT PEPTIDES THEREOF, AND ANALOGS THEREOF TO PROMOTE

NEURAL CELL DIFFERENTIATION

## **CERTIFICATION**

Under 1.97(e)(1), the undersigned attorney hereby certifies that WO 95/30686 contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

When the Examiner takes up the present application, consideration of these documents is respectfully requested. The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

## **CERTIFICATE UNDER 37 C.F.R. 1.8:**

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on this 23rd day of July, 2001

nn M. Mueting

July 23, 2001

Date

Respectfully submitted,

Stanton et al.

By their Representatives, Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Telephone: (612) 305-1220 Facsimile:

(612) 305-1228

By: Ann M. Mueting

Reg. No. 33,977

Direct Dial (612) 305-1217